PDS Biotechnology will report Q1 2026 results before market open, with a consensus EPS estimate of -$0.14 and $0M revenue.
PDS Biotechnology (PDSB) will announce its Q1 2026 earnings on Wednesday, May 13, ahead of the market opening. Analysts expect a loss of $0.14 per share, reflecting a 33.3% improvement year-over-year, alongside revenue of $0M.
Over the past three months, EPS estimates have seen one upward revision with no downward adjustments. The company has not provided additional guidance or context for the upcoming results.
Markets will focus on the earnings report for signs of progress in PDS Biotech’s pipeline and financial health.